key: cord-0883889-m9amhxyi authors: Kim, Boa; Arany, Zolt title: Could shear stress mimetics delay complications in COVID-19? date: 2021-01-27 journal: Trends Cardiovasc Med DOI: 10.1016/j.tcm.2021.01.004 sha: cceea7aa0c8acb7883974415d1c07b2c187837df doc_id: 883889 cord_uid: m9amhxyi nan Coronavirus disease of 2019 continues to plague the world, and it is likely here to stay indefinitely, even if vaccines are successful. Covid-19 is in fact both a pulmonary and endothelial disease 1 . SARS-CoV2 uses the angiotensin converting enzyme 2 (ACE2) to facilitate entry into cells, and ACE2 is present widely on lung type II alveolar cells and on ECs throughout the body. Continuous endothelium, as found in heart and muscle, is infected by SARS-CoV prior to crossing to underlying parenchyma. Endotheliitis is a hallmark of end-stage disease 2 . Micro and macrovascular EC dysfunction leads to vasoconstriction, pro-coagulant and proinflammatory states, and ultimately to end-organ dysfunction, all hallmarks of terminal COVID- 19 . Patients with pre-existing endothelial dysfunction, i.e. the aged, smokers, and subjects with hypertension or diabetes, are precisely the groups at highest risk for COVID-19 complications and mortality. There is thus strong rationale for using strategies of endothelial-targeted therapy or vascular normalization to prevent or delay complications, allowing time for immunological responses to clear the virus. The only vasculo-protective approach taken to date has been with 3-hydroxy-3-methyl-glutrayl-coenzyme A reductase inhibitors (statins), with mixed results. Another interesting consideration would be to somehow promote endothelial sheer stress (ESS) signaling. ESS is defined as the tangential force exerted upon the endothelial surface by friction from flowing blood. ESS is proportional to the viscosity of blood and its velocity at the vessel wall. The velocity at the vessel wall, in turn, is dictated by the magnitude of blood flow in the vessel and by the nature of the flow. Blood flow velocity in vessels ranges from 100 cm/sec in aorta to 0.5 mm/sec in capillaries, a 2000-fold range. The rate of change of flow, i.e. acceleration, is also important to ESS, and can be as high as 6000 cm/sec2, the equivalent of 6 g-force (6 times earth's gravity). Flow is pulsatile in arterial vessels, due to the cardiac cycle, and can even be Multiple GPCRs have potential mechanosensing properties, including GPR68 15 , the Sphingosine-1-phosphate receptors (S1PR) 16 , the histamine receptors 17 , and the bradykinin receptors 18 . GPCRs are widely expressed transmembrane proteins that, in general, bind to agonists that cause transmission of information to the intracellular milieu via allosteric changes in the receptor, leading to recruitment of intracellular signaling molecules such as heterotrimeric Gproteins or β-arrestins. Xiucun Li et al. 14 discusses in depth potential mechanisms of mechanosensing by different GPCRs, both agonist-dependent and agonist-independent, including conformational changes that can be triggered by ESS-induced changes in plasmalemma tension and membrane fluidity. Xiucun Li et al. also discusses the connection between reactive hyperemia (RH) and GPCRs. Although the mechanism of how the postocclusive RH works has been controversial, GPCR Gq/11-mediated signaling that releases endothelium-derived hyperpolarization factor (EDHF) or nitric oxide (NO) seem to be responsible for the hyperemic response. In addition to GPCRs, a few ion channels including PIEZO1 19 and transient receptor potential vanilloid-4 (TRPV4) 20 have been identified as mechanosensitive and contribute significantly to the regulation of vascular tone by working synergistically with GPCRs. Could there be a use for pharmacological activation of ESS pathways, i.e. ESS mimetics, in treating the current global COVID-19 scourge? There is indirect evidence for the idea that ESS mimetics might be protective against COVID-19 complications. The biological consequences of activated mechanotransduction in ECs are complex and differ contextually, but a major and consistent result is the activation of NO production by endothelial NO synthase (eNOS). NO, in turn, promotes vascular relaxation, and is also strongly anti-inflammatory, anti-thrombotic, and anti-apoptotic. NO decreases with age and with diabetes, the two groups most affected by COVID-19. Interestingly, NO has been shown to inhibit SARS-CoV1 replication 21, 22 . Inhaled NO has shown potential benefit in SARS-CoV1 infections 23 , and case studies suggest possible benefit in COVID-19 [24] [25] [26] . Phase 2 clinical trials with inhaled NO in COVID-19 are ongoing (NCT04388683, NCT04338828, NCT04397692, NCT04456088). Putative ESS mimetics would be expected to activate NO production, in addition to numerous other vasculo-protective pathways described above, thus yielding similar benefit as NO, if not more. GPCRs are eminently tractable pharmaceutical targets, accounting for ~30% of FDA-approved drugs, and >$150 billion annual sales worldwide. Targeting GPCRs that mediate ESS, guided by Xiucun Li and others, 14 could thus be an attractive alternative to promote vasculoprotection in COVID-19. COVID-19 -A vascular disease Endothelial cell infection and endotheliitis in COVID-19 Arterial wall shear and distribution of early atheroma in man The atherosusceptible endothelium: endothelial phenotypes in complex haemodynamic shear stress regions in vivo Turbulent blood flow in the ascending aorta of humans with normal and diseased aortic valves Inflammatory responses of endothelial cells experiencing reduction in flow after conditioning by shear stress KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium Fluid shear stress threshold regulates angiogenic sprouting Role of G proteins in shear stress-mediated nitric oxide production by endothelial cells Ion Channels in Endothelial Responses to Fluid Shear Stress Piezo1 integration of vascular architecture with physiological force shear stress and muscle angiogenesis: a complicated triangle Integrin-mediated mechanotransduction requires its dynamic interaction with specific extracellular matrix (ECM) ligands Flow-mediated vasodilation through mechanosensitiveG protein-coupled receptors in endothelial cells. Trends in Cardiovasc Med GPR68 Senses Flow and Is Essential for Vascular Physiology Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development Helix 8 is the essential structural motif of mechanosensitive GPCRs G protein-coupled receptors sense fluid shear stress in endothelial cells Shear stressinduced endothelial adrenomedullin signaling regulates vascular tone and blood pressure TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus Activation of toll-like receptor signaling pathways leading to nitric oxide-mediated antiviral responses Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension Rescue Treatment With High-Dose Gaseous Nitric Oxide in Spontaneously Breathing Patients With Severe Coronavirus Disease High Concentrations of Nitric Oxide Inhalation Therapy in Pregnant Patients With Severe Coronavirus Disease 2019 (COVID-19)